CSL
sept 2026
Team invest love this business.
Huge moats
...................
Over the past five years, ASX:CSL has seen steady revenue and underlying profit growth, but a significant increase in debt due to the Vifor acquisition. This has pressured its Return on Equity (ROE) and recent share price, leading the company to announce a major restructuring in 2026. [1, 2, 3, 4]
Key 5-Year Financial Metrics
- Profit: Historically trending upwards, with Net Profit After Tax (NPAT) sitting near A$3.3 billion in FY 2024 and A$3.0 billion for FY 2025. However, profit downgrades and asset impairments throughout the 2026 financial year have impacted recent short-term earnings. [1, 2, 3]
- Debt: Net debt has grown substantially to approximately A$10 billion, driven primarily by the 2022 acquisition of CSL Vifor. This puts its net debt-to-equity ratio at a manageable but elevated ~0.50x to 0.60x. [1, 2, 3]
These are the D/E ratios for the last 5 years:
2026 - 0.52
2025 - 0.54
2024 - 0.63
2023 - 0.69
2022 - 0.66
- Return on Equity (ROE): Has trended downwards. While ROE peaked near 31.9% in 2021 (partly due to pandemic-related distortion), it has since stabilized at more normal levels, tracking around 15.4% in 2024 and shifting to roughly 15.37% in 2025 before softening further in 2026. [1, 2, 3]
- Share Price: CSL has been under heavy technical pressure and has declined roughly 55% over a 5-year period, trading well below its 200-day moving average. [1, 2]
- Dividends - about 3.3% No franking so keep in super.
Recent Restructuring & Outlook
You can track CSL’s live share performance and historical announcements by visiting the ASX Market Updates page or viewing the full investor reports on the CSL Investor Centre.
.....................
PE Ratios
CSL Limited (ASX: CSL) has traded at a 10-year historical mean P/E ratio of approximately 51.61, with a more recent 5-year median of 38.62. Historically valued as a high-growth market darling, its trailing P/E ratio compressed down to a 5-year low of 26.5x in June 2025. This compression followed earnings adjustments and a falling share price. As of July 2026, the company's valuation varies depending on the specific reporting standards utilized (e.g., statutory vs. underlying or localized TTM numbers), positioning its standard P/E ratio around 26x to 28.4x. [1, 2, 3, 4]
Historical 10-Year P/E Ratio Breakdown
The following table provides the historical fiscal year-end (June 30) Price-to-Earnings ratios for CSL over the past decade based on financial tracking data from platforms like Market Index, Investing.com, and Finbox:
| Fiscal Year Ending [1, 2, 3, 4, 5] | Approximate P/E Ratio | Valuation Context & Drivers |
|---|---|---|
| FY 2025 | 25.6x – 26.5x | 5-year low; severe price pullback despite steady core plasma collections. |
| FY 2024 | 35.1x – 37.2x | Margin pressures from higher plasma donor fees and inflationary pressures. |
| FY 2023 | 41.3x | Post-pandemic recovery peak; optimism around Vifor integration and plasma volume bounce-back. |
| FY 2022 | 39.1x | Moderate recovery from COVID-19 plasma collection constraints. |
| FY 2021 | 38.6x | Initial earnings hit during the height of lockdowns affecting global donor centers. |
| FY 2020 | 48.2x (Peaked at 77.1x) | All-time high operational multiple prior to severe lockdown impacts on plasma supply. |
| FY 2019 | 42.5x | High-growth premium driven by strong demand for immunoglobulin products. |
| FY 2018 | 37.8x | Robust EPS growth resulting in a temporarily lower tracking multiple. |
| FY 2017 | 41.0x | Sustained market premium as a top three ASX-listed company by market cap. |
| FY 2016 | 36.2x | Stable baseline era featuring lower operational costs. |
Key Valuation Factors to Consider
- The 2020 Valuation Peak: CSL’s P/E ratio reached an intraday/quarterly peak of 77.15x in June 2020. Investors priced in massive growth right before global border closures hampered plasma collections. [1, 2]
- Structural P/E Compression: The downward shift toward a P/E under 30x in 2025/2026 represents a significant change for a company that spent a decade comfortably trading above 35x. [1, 2]
- Forward Outlook: According to consensus tracking on Stock Analysis, CSL's forward-looking P/E drops significantly to around 13.3x. This forward projection implies analysts expect a major structural earnings per share (EPS) recovery over the next 12 to 24 months. [1, 2]
....................
ROIC Vs WACC
Over the last 10 years, CSL Limited has historically maintained an ROIC well above its WACC, though recent compressed earnings have narrowed the spread. [1]
- ROIC Trend: Historically averaged between 10% and 15% over the decade, though recent trailing metrics place it around 8.4% to 10.4%.
- WACC Trend: Historically hovered around a 10-year median of roughly 6.9% to 8.2%, with current estimates sitting near 6.0% to 8.2%.
..............
ARGO vs CSL Buffett style sept 2026
Comparing Argo Investments (ASX:ARG) and CSL Limited (ASX:CSL) through a Warren Buffett-style lens reveals two entirely different manifestations of an economic moat: a diversified, low-cost financial compounder versus a dominant global operational monopoly.
1. Business Model & Economic Moat (The Buffett Test)
- ARG (Argo Investments): A Listed Investment Company (LIC) that acts as a diversified vehicle pooling capital into a basket of Australian blue chips.
- CSL (CSL Limited): A global biotech leader in plasma therapeutics and vaccines.
2. Long-Term 10-Year Growth
- ARG: Delivers steady, index-tracking capital growth closely aligned with the broader Australian market, compounded by disciplined reserve management to smooth out market downturns. Its 10-year total shareholder return historically hovers around 7–9% annualized including dividends. [1, 2]
- CSL: Historically functions as an exceptional long-term compounder. Over 20 years, CSL has compounded at roughly 17% p.a., significantly outperforming the index, though the last few years have featured macro and plasma-cost headwinds that slowed short-term momentum. [1]
3. Price-to-Earnings (P/E) Ratio
- ARG: Trades at a trailing P/E of roughly 26.9x, sitting slightly above its 10-year median (~25.6x). Because it holds equities valued at market prices, its P/E reflects overall market valuations. [1]
- CSL: Trades at a normalized trailing P/E of around 25x to 30x (historical multi-year median near 32x+), which compresses during cyclical margin squeezes but generally commands a heavy growth premium due to its global healthcare status.
4. Dividend & Dividend Growth
- ARG (The Income Specialist):
- CSL (The Reinvestment Compounder):
- Yield: Low, hovering around 1.4% to 2.3%.
- Franking: 0% (unfranked/minimally franked due to global offshore earnings).
- Growth: CSL historically grows its absolute dividend payout at a double-digit clip over rolling multi-year horizons (averaging high single-digits to 10%+), but management prefers retaining excess capital to plow back into high-return R&D and plant expansions. [1, 2, 3, 4, 5, 6]
Buffett-Style Verdict
........................
More Buffett analysis
An analysis of CSL Ltd (ASX: CSL) reveals a significant shift in its historical efficiency metrics and capital allocation framework, especially when evaluated against Warren Buffett’s benchmarks. [1]
The company has historically been a premier compounding engine on the ASX. However, recent structural changes and aggressive acquisitions have materially altered its financial profile. [1, 2, 3]
1. Historical Return on Equity (ROE) Trends
Historically, CSL was characterized by an exceptionally high, stable ROE, routinely averaging 20% to 25% over the decade leading into the 2020s. This reflected a highly lucrative, capital-light plasma fractionalization model coupled with strong global pricing power. [1]
However, the trend over the last five years shows a clear deceleration followed by a sharp accounting shock:
- FY2022: 19.6% — A strong performance, though compressed from historical peaks due to elevated pandemic-era plasma collection costs. [1]
- FY2023 – FY2025: 14.5% to 16.4% — Rebounding slightly but establishing a lower structural baseline. This compression was driven by the US$11.7 billion acquisition of Vifor Pharma in late 2022, which bloated the equity base with over $16 billion in goodwill and intangibles. [1, 2, 3]
- FY2026 (The Reset): -15.1% to -15.8% — CSL booked a massive statutory net loss of US$2.58 billion. This was caused by approximately US$5 billion in non-cash asset impairments (primarily related to the Vifor/kidney treatment business), alongside restructuring costs and a delayed spin-off of its Seqirus vaccine division. [1, 2, 3, 4, 5]
2. Capital Allocation vs. Buffett Benchmarks
Warren Buffett utilizes clear, stringent metrics to evaluate corporate management's capital efficiency. Evaluating CSL against these classic hurdles highlights its current strategic crossroads. [1]
| Buffett Benchmark | Buffett Requirement | CSL Performance (Current Profile) | Assessment |
|---|---|---|---|
| Sustained ROE | > 15% consistently over 10 years | 10.3% (5-year average); structurally negative in FY26 due to write-downs. | Underperforms recently, but passes on a historical/underlying operational basis. |
| Debt-to-Equity | < 0.50 (Prefers low leverage for safety) | 0.67 (Current Net Debt/Equity is ~49%). | Moderate Risk. Leverage increased to fund the Vifor deal. |
| Capital Intensity | Prefers Capital-Light compounders | High. Requires constant capex for plasma centers and complex biologics manufacturing. | Misses. CSL is inherently a capital-intensive manufacturer. |
| The "Dollar Test" | Every $1 retained must create > $1 in market value | Underperformed recently as the market digested acquisition premium and lower growth guidance. | Failing (Short-term); Passing (Long-term). |
Strategic Deviations from the Buffett Playbook
- The M&A Trap vs. Organic Growth: Buffett famously prefers organic expansion or bolt-on acquisitions where he has absolute certainty of earnings power. CSL's acquisition of Vifor represents a deviation into large-scale M&A. The resulting US$5 billion write-down in FY26 is a textbook example of what Buffett warns against: overpaying for growth that fails to materialize at predicted margins. [1, 2, 3, 4]
- The Illusion of ROE vs. ROIC: Buffett often stresses looking at both ROE and ROIC to evaluate if debt is masking inefficiency. In CSL's case, the relationship is inverted due to accounting rules. CSL's ROIC of 16.51% tells us the business is actually fundamentally sound, but its reported ROE was crushed by the massive equity-side asset impairment. [1, 2, 3, 4]
The Bottom Line
Historically, CSL would have been a quintessential "Buffett-style" wonderful company. Today, its capital allocation has become more complex. Management is currently navigating a structural reset—slashing costs, attempting to demerge underperforming units (Seqirus), and driving efficiency to lift underlying NPAT growth back toward 5% in FY2027. For long-term investors, the core question is whether management can successfully return its expanded asset base to those historical >20% capital return frameworks. [1, 2, 3]
....................
No comments:
Post a Comment